AR099676A1 - MULTIMERIC FC PROTEINS - Google Patents
MULTIMERIC FC PROTEINSInfo
- Publication number
- AR099676A1 AR099676A1 ARP150100664A ARP150100664A AR099676A1 AR 099676 A1 AR099676 A1 AR 099676A1 AR P150100664 A ARP150100664 A AR P150100664A AR P150100664 A ARP150100664 A AR P150100664A AR 099676 A1 AR099676 A1 AR 099676A1
- Authority
- AR
- Argentina
- Prior art keywords
- fusion protein
- multimeric fusion
- protein according
- polypeptide
- monomer unit
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Una proteína de fusión multimérica que comprende dos o más unidades de monómero de polipéptido caracterizada porque; cada unidad de monómero de polipéptido comprende un dominio Fc de anticuerpo que comprende dos regiones Fc de la cadena pesada; cada región Fc de la cadena pesada comprende cualquier residuo de aminoácido distinto de cisteina en la posición 309, y está fusionado en su extremo C-terminal a un apéndice que provoca que las unidades de monómero se monten en un multímero; la unidad de monómero de polipéptido no comprende una región variable de anticuerpo. Reivindicación 51: Una secuencia de ADN aislada caracterizada porque codifica una cadena de polipéptido de una unidad de monómero de polipéptido de una proteína de fusión multimérica de acuerdo con cualquier reivindicación precedente, o una parte componente de la misma. Reivindicación 56: Una composición farmacéutica caracterizada porque comprende una proteína de fusión multimérica de acuerdo con cualquiera de las reivindicaciones 1 a 50, en combinación con un excipiente, diluyente o portador aceptable para uso farmacéutico. Reivindicación 58: La proteína de fusión multimérica de acuerdo con la reivindicación 57 caracterizada porque es para su uso en el tratamiento de trastornos del sistema inmune. Reivindicación 60: La proteína de fusión multimérica de acuerdo con la reivindicación 58, o el uso de acuerdo con la reivindicación 59, caracterizada porque el trastorno inmunológico se selecciona de trombocitopenia inmune, síndrome de Guillain-Barré, enfermedad de Kawasaki, y la polineuropatía desmielinizante inflamatoria crónica.Claim 1: A multimeric fusion protein comprising two or more polypeptide monomer units characterized in that; each polypeptide monomer unit comprises an antibody Fc domain comprising two Fc regions of the heavy chain; each Fc region of the heavy chain comprises any amino acid residue other than cysteine at position 309, and is fused at its C-terminal end to an appendix that causes the monomer units to be mounted in a multimer; The polypeptide monomer unit does not comprise a variable region of antibody. Claim 51: An isolated DNA sequence characterized in that it encodes a polypeptide chain of a polypeptide monomer unit of a multimeric fusion protein according to any preceding claim, or a component part thereof. Claim 56: A pharmaceutical composition characterized in that it comprises a multimeric fusion protein according to any one of claims 1 to 50, in combination with an excipient, diluent or carrier acceptable for pharmaceutical use. Claim 58: The multimeric fusion protein according to claim 57 characterized in that it is for use in the treatment of immune system disorders. Claim 60: The multimeric fusion protein according to claim 58, or the use according to claim 59, characterized in that the immune disorder is selected from immune thrombocytopenia, Guillain-Barré syndrome, Kawasaki disease, and demyelinating polyneuropathy chronic inflammatory
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403912A GB201403912D0 (en) | 2014-03-05 | 2014-03-05 | Proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099676A1 true AR099676A1 (en) | 2016-08-10 |
Family
ID=50490855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100664A AR099676A1 (en) | 2014-03-05 | 2015-03-05 | MULTIMERIC FC PROTEINS |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR099676A1 (en) |
| GB (1) | GB201403912D0 (en) |
-
2014
- 2014-03-05 GB GB201403912A patent/GB201403912D0/en not_active Ceased
-
2015
- 2015-03-05 AR ARP150100664A patent/AR099676A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201403912D0 (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211272A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| BR112016020368A2 (en) | multimeric fc proteins | |
| CO2017002166A2 (en) | Interleukin 2 / interleukin-2 alpha receptor fusion proteins | |
| AR099288A1 (en) | INTERLEUCINE FUSION PROTEINS-10 | |
| PH12018500269A1 (en) | Constructs having a sirp-alpha domain or variant thereof | |
| CO2018003863A2 (en) | Anti-vegf antibodies | |
| BR112016016411A2 (en) | "Fc"-REGION VARIANTS WITH MODIFIED "FcRn" BINDING PROPERTIES | |
| CY1123450T1 (en) | IL-15/IL-15RA BASED CONJUGATE PURIFICATION METHOD | |
| CR20190209A (en) | Immunoglobulins and uses thereof | |
| MX2020010061A (en) | Fc-region variants with modified fcrn-binding and methods of use. | |
| BR112017007816A2 (en) | pharmaceutical compositions comprising peptide variants and methods of using them | |
| AR107290A1 (en) | PEPTIDE ANTIBODIES b AMILOID ANTI-N3pGlu AND USES OF THE SAME | |
| BR112014029966A2 (en) | fibroblast growth factor proteins 21 | |
| PH12021550822A1 (en) | Compositions and methods for the treatment of viral infections | |
| PE20131141A1 (en) | MONOCLONAL ANTIBODY | |
| EP3554544A4 (en) | Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof | |
| CY1123719T1 (en) | FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS FOR GENERATION OF REGULARLY POLYMERIZED FC IMMUNOSPHEREIN CONSTITUTES WITH ENHANCED COMPLEMENT BINDING | |
| PE20190110A1 (en) | RSV PREFUSION F PROTEINS STABILIZED | |
| BR112019004459A2 (en) | methods for purifying antibodies | |
| IL276616A (en) | Dosing for treatment with il-22 fc fusion proteins | |
| EA201892554A1 (en) | MUTANT CD200 AND ITS APPLICATIONS | |
| PH12019501064A1 (en) | Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | |
| NZ754606A (en) | Anti-il-5 antibodies | |
| MA46863A (en) | INTRATHECAL ADMINISTRATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS CODING FOR METHYL-CPG-BINDING PROTEIN 2 | |
| AR099676A1 (en) | MULTIMERIC FC PROTEINS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |